Related references
Note: Only part of the references are listed.CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
Tanaya Shree et al.
BLOOD CANCER DISCOVERY (2022)
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
Maria P. Sormani et al.
ANNALS OF NEUROLOGY (2021)
Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis
Frederik Novak et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)
Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy
Sachin P. Gadani et al.
EBIOMEDICINE (2021)
Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy
Tobias Moser et al.
BIOMEDICINES (2021)
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
David S. Khoury et al.
NATURE MEDICINE (2021)
Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses
F. Javier Ibarrondo et al.
ACS NANO (2021)
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
Sokratis A. Apostolidis et al.
NATURE MEDICINE (2021)
The role of TH17 cells in multiple sclerosis: Therapeutic implications
Tobias Moser et al.
AUTOIMMUNITY REVIEWS (2020)
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis
David Baker et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS
Tobias Moser et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
David Baker et al.
EBIOMEDICINE (2017)
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos et al.
LANCET (2011)
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
Mohammad Tabrizi et al.
AAPS JOURNAL (2010)
Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice
David J. DiLillo et al.
JOURNAL OF IMMUNOLOGY (2008)